REM sleep behavior disorder: A possible early marker for synucleinopathies
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Boeve and Saper propose that REM sleep behavior disorder (RBD) be considered an early clinical marker for neurodegenerative diseases with α-synuclein aggregation,1 a proposal advanced earlier by Boeve et al.2
While RBD can be a sentinel event in these diseases, it is not specific for synucleinopathy, even in the universe of neurodegenerative disorders. As noted in their editorial, RBD has been reported in patients with progressive supranuclear palsy.3 We have followed several families in southeastern New England with Machado-Joseph disease (MJD) (SCA-3). The ataxin-3 protein which accumulates in MJD has an expanded polyglutamine domain, and is biochemically distinct from α-synuclein. In our patient population, clinical features suggestive of RBD were identified in a high proportion of affected individuals.4 This association has been confirmed with polysomnography by Iranzo et …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. David Beversdorf and Dr. Ryan Townley
► Watch
Related Articles
- No related articles found.
Alert Me
Recommended articles
-
Articles
Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophyA. M. Schmeichel, L. C. Buchhalter, P. A. Low et al.Neurology, January 28, 2008 -
Article
REM behavior disorder predicts motor progression and cognitive decline in Parkinson diseaseGennaro Pagano, Rosa De Micco, Tayyabah Yousaf et al.Neurology, August 08, 2018 -
Views & Reviews
Update on the pharmacology of REM sleep behavior disorderJean-François Gagnon, Ronald B. Postuma, Jacques Montplaisir et al.Neurology, September 11, 2006 -
Articles
Stages of sleep pathology in spinocerebellar ataxia type 2 (SCA2)I. Tuin, U. Voss, J. -S. Kang et al.Neurology, December 11, 2006